<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317225</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2011-01</org_study_id>
    <nct_id>NCT01317225</nct_id>
  </id_info>
  <brief_title>Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone</brief_title>
  <official_title>Use of 17α Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor During Current Pregnancy. Double Blind, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of 250 mg of intramuscular progesterone
      biweekly can reduce the incidence of preterm labor in patients with an episode of threatened
      preterm labor during the current pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm birth is one of the main causes of neonatal mortality and morbidity around the world,
      with serious repercussions on the health system and the families of the preterm baby. Many
      drugs have been evaluated with the purpose of preventing preterm birth in the patient at
      risk. One of these drugs is 17 α hydroxyprogesterone caproate. The purpose of this study is
      to evaluate if the use of biweekly doses of 17 α hydroxyprogesterone caproate in patients
      hospitalized with the diagnosis of threatened preterm labor, defined as the presence of
      uterine contractions and a short cervix (below the 10th percentile for the gestational age),
      can reduce the incidence of preterm birth in this high risk group population.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of preterm birth (before 37 weeks of gestation)</measure>
    <time_frame>18 months</time_frame>
    <description>Number of patients that delivered before 37 weeks of pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of preterm birth before 35 weeks of pregnancy</measure>
    <time_frame>18 months</time_frame>
    <description>To determine if the use of 17 α hydroxyprogesterone caproate can reduce the incidence of preterm birth before 35 weeks of gestation in patients with a previous episode of threatened preterm labor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preterm birth before 32 weeks of pregnancy</measure>
    <time_frame>18 months</time_frame>
    <description>To determine if the use of 17 α hydroxyprogesterone caproate can reduce the incidence of preterm birth before 32 weeks of gestation in patients with a previous episode of threatened preterm labor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>17 α hydroxyprogesterone caproate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17α-Hydroxyprogesterone caproate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 α hydroxyprogesterone caproate</intervention_name>
    <description>250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.</description>
    <arm_group_label>17 α hydroxyprogesterone caproate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women between 26 and 34 weeks of gestation.

          -  Cervical length (determined by transvaginal ultrasound) below the 10th percentile for
             the gestational age.

        Exclusion Criteria:

          -  Multiple gestations.

          -  Maternal pathologies in which preterm termination of pregnancy is required.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo A Reyes, MD (Gyn/Ob)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Velarde, MD (Gyn/Ob)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osvaldo A Reyes, MD (Gyn/Ob)</last_name>
    <phone>011(507)65655041</phone>
    <email>oreyesmaternidad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodrigo Velarde, MD (Gyn/Ob)</last_name>
    <phone>011(507)66159954</phone>
    <email>revelarde_14@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Thomas Maternity Hospital</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo A Reyes, MD (Gyn/Ob)</last_name>
      <phone>011(507)65655041</phone>
      <email>oreyesmaternidad@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rodrigo Velarde, MD (Gyn/Ob)</last_name>
      <phone>011(507)66159954</phone>
      <email>revelarde_14@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Osvaldo A Reyes, MD (Gyn/Ob)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Velarde, MD (Gyn/Ob)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <last_update_submitted>January 3, 2015</last_update_submitted>
  <last_update_submitted_qc>January 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>Obstetric labor, premature</keyword>
  <keyword>Short cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

